CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-05 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.68 | $154K | 1,273,156 |
| 2025-02-05 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,956,700 | ||
| 2025-02-03 | Taylor Ben R Chief Financial Officer | Grant or award | +35,018 | 879,228 | ||
| 2025-02-03 | Taylor Ben R Chief Financial Officer | Grant or award | +13,922 | 893,150 | ||
| 2025-02-03 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −6,544 | $7.25 | $47K | 886,606 |
| 2025-02-03 | Taylor Ben R Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +70,037 | 70,037 | ||
| 2025-02-03 | Khan Najat Chief R&D Commercial Officer | Grant or award | +210,113 | 707,085 | ||
| 2025-02-03 | Khan Najat Chief R&D Commercial Officer | Grant or award | +8,049 | 715,134 | ||
| 2025-02-03 | Khan Najat Chief R&D Commercial Officer | Shares withheld for taxes | −2,753 | $7.25 | $20K | 712,381 |
| 2025-02-03 | Khan Najat Chief R&D Commercial Officer | Grant or award · Stock Option (Right to Buy) | +420,226 | 420,226 | ||
| 2025-02-03 | Gibson Christopher Chief Executive Officer | Grant or award | +525,283 | 1,261,916 | ||
| 2025-02-03 | Gibson Christopher Chief Executive Officer | Grant or award | +16,809 | 1,278,725 | ||
| 2025-02-03 | Gibson Christopher Chief Executive Officer | Shares withheld for taxes | −5,569 | $7.25 | $40K | 1,273,156 |
| 2025-02-03 | Gibson Christopher Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +1,050,567 | 1,050,567 | ||
| 2025-01-10 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 756,633 | ||
| 2025-01-10 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.05 | $141K | 736,633 |
| 2025-01-10 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,976,700 | ||
| 2025-01-08 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +20,000 | 756,633 | ||
| 2025-01-08 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −20,000 | $7.31 | $146K | 736,633 |
| 2025-01-08 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −20,000 | 5,996,700 |
Page 11 of 41 · 805 trades